布苏尔班
医学
加药
药物遗传学
基因型
造血干细胞移植
药理学
干细胞
药代动力学
造血
造血干细胞
肿瘤科
免疫学
毒性
内科学
造血细胞
治疗药物监测
移植
化疗
不利影响
癌症研究
作者
Bushra Mustafa Salman,Intisar Al Riyami,Raya Al Maskari,Murtadha K. Al-Khabori
标识
DOI:10.1097/fpc.0000000000000589
摘要
OBJECTIVE: This study examined the impact of glutathione- S -transferase polymorphisms (GSTA1, GSTM1, GSTP1, and GSTT1) on the area under the curve (AUC), clearance, veno-occlusive disease (VOD), and graft-versus-host disease (GvHD) in hematopoietic stem cell transplant (HSCT) patients treated with intravenous busulfan. METHODS: A systematic review was performed on three electronic databases to identify relevant studies. The relative risk and the 95% confidence interval (CI) of the association of different GST polymorphisms with pharmacokinetic and clinical outcomes were reported using the random and fixed effect models. Quality of the studies was assessed using the Newcastle-Ottawa Scale for cohort studies. Heterogeneity between studies and publication bias were also carried out using R software. RESULTS: Eighteen studies were included in the meta-analysis. GSTA1*A/*B was significantly associated with lower clearance (95% CI: 0.008-1.223, P = 0.048) and higher AUC (95% CI: -374.960 to -56.661, P = 0.008) than the GSTA1*A/*A genotype. GSTA1*B/*B had a higher busulfan AUC than GSTA1*A/*A (95% CI: -403.531 to -89.454, P = 0.002). None of the other genotypes was significantly associated with busulfan pharmacokinetic parameters or the risk of VOD or GvHD. CONCLUSION: GSTA1 should be considered as a guide for intravenous busulfan dosing in allogeneic HSCT patients, where patients with the GSTA1*A/*A genotype require a higher dose than GSTA1*B carriers.
科研通智能强力驱动
Strongly Powered by AbleSci AI